# Evaluating the Use of a Medication 'Switch' vs Guideline-directed Interventions for Relieving Side Effects of Aromatase Inhibitors Among Breast Cancer Patients

> **NCT07071038** · PHASE2 · RECRUITING · sponsor: **Dartmouth-Hitchcock Medical Center** · enrollment: 62 (estimated)

## Conditions studied

- Breast Cancer
- Adjuvant Treatment
- Early Stage Breast Cancer

## Interventions

- **DRUG:** Switch
- **OTHER:** Guideline Directed Intervention (GDI)

## Key facts

- **NCT ID:** NCT07071038
- **Lead sponsor:** Dartmouth-Hitchcock Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-10-17
- **Primary completion:** 2026-08-05
- **Final completion:** 2027-08-05
- **Target enrollment:** 62 (ESTIMATED)
- **Last updated:** 2026-02-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07071038

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07071038, "Evaluating the Use of a Medication 'Switch' vs Guideline-directed Interventions for Relieving Side Effects of Aromatase Inhibitors Among Breast Cancer Patients". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT07071038. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*